

Kobe University Repository : Kernel

PDF issue: 2025-05-24

Which symptoms negatively affect the oral health-related quality of life in patients with osteonecrosis of the jaw?

Sato, Takumi ; Kusumoto, Junya ; Takeda, Daisuke ; Kishimoto, Megumi ; Kashin, Masahiko ; Furudoi, Shungo ; Akashi, Masaya

(Citation)

Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 130(2):175-180

(Issue Date) 2020-08

(Resource Type) journal article

(Version) Accepted Manuscript

(Rights)

© 2020 Elsevier Inc. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/

(URL)

https://hdl.handle.net/20.500.14094/90007564



1		
2 3 4	1	Which symptoms negatively affect the oral health-related quality of life in patients with
5 6	2	osteonecrosis of the jaw?
8 9	3	
10 11	4	Takumi Sato, DDS ^{a†} , Junya Kusunoto, DDS ^{a‡} , Daisuke Takeda, DDS, PhD ^{a‡} , Megumi
12 13 14	5	Kishimoto, DDS, PhD ^{a†} , Masahiko Kashin, DDS ^{a†} , Shungo Furudoi, DDS, PhD ^{bl} , Masaya
15 16	6	Akashi, DDS, PhD ^{a*¶}
17 18 19	7	†Clinical fellow, ‡Assistant Professor, IChief, Associate Professor, IProfessor and Chairman
20 21	8	^a Department of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine,
22 23 24	9	Kobe, Japan
24 25 26	10	^b Department of Oral and Maxillofacial Surgery, Kohnan Medical Center, Kobe, Japan
27 28 20	11	
29 30 31	12	*Corresponding author:
32 33	13	Masaya Akashi, D.D.S, Ph.D., Department of Oral and Maxillofacial Surgery, Kobe University
34 35 36	14	Graduate School of Medicine, Kusunoki-cho 7-5-2, Chuo-ku, Kobe 650-0017, Japan
37 38	15	Tel: +81-78-382-6213; Fax: +81-78-382-6229
39 40 41	16	E-mail: akashim@med.kobe-u.ac.jp
42	17	
43 44 45	18	Word count for the abstract: 189
46 47 48	19	Manuscript word count (to include body text and figure legends): 2118
49 50	20	Number of references: 24
51 52	21	Number of figures/tables: 0/4
53 54 55	22	
56 57	23	Declarations of interest
58 59 60	24	None.
61		1
62 63		
64		

1	Statement of Clinical Relevance
2	Quality of life was reduced because of painful aching in patients with osteoradionecrosis of the
3	jaw. Moreover, worsened taste was experienced by patients with medication-related
4	osteonecrosis of the jaw.
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
	2

1 Abstract

 Objectives. One of the treatment goals for osteonecrotic lesions of the jaw, such as medicationrelated osteonecrosis of the jaw (MRONJ) or osteoradionecrosis (ORN), is restoration of quality
of life (QOL). This study aimed to identify symptoms that negatively affected QOL in patients
with unhealed MRONJ or ORN.

Study Design. This cross-sectional study included patients who were previously diagnosed with

7 MRONJ or ORN and who underwent treatment at our hospital between June 2015 and February

8 2016. Patient QOL was measured using the Oral Health Impact Profile (OHIP-14). The

9 predictor variable was the disease status (stage and healing). The outcome variable was

OHIP-14. One-way analysis of variance **and Tukey's test** were performed.

Results. 74 patients (37 men and 37 women; mean age, 70 years) were included. Although

12 there was no significant difference of OHIP-14 score among stage 1-3 of unhealed MRONJ

13 and ORN and healed ones, the "worsened sense of taste" result significantly differed among

stages in patients with unhealed MRONJ (*P*=0.027) and the "painful mouth aching" in patients

15 with unhealed ORN (P=0.041).

16 Conclusions. Worsened sense of taste and pain negatively affected the QOL in patients with17 unhealed MRONJ and ORN.

Key words: medication-related osteonecrosis of the jaw; osteoradionecrosis of the jaw; quality
of life; Oral Health Impact Profile.

1 Introduction

Osteonecrotic lesions of the jaw, such as medication-related osteonecrosis of the jaw (MRONJ) and osteoradionecrosis (ORN), are uncommon but problematic adverse effects of medical treatments for malignant tumors. Anti-resorptive agents including bisphosphonates and anti-receptor activator of nuclear factor κ - β ligand antibody have been used as treatment for bone metastasis and osteoporosis; these drugs cause osteonecrosis in 1-15% of patients with cancer and 0.001–0.1% of patients with osteoporosis.¹ ORN of the jaw is a complication of radiation therapy for head and neck malignancy. Although ORN occurs in 5–15% of patients within the first 3 years after completion of radiation therapy,² ORN can occur regardless of the post-treatment interval.³

Although there is no defined treatment algorithm thus far, the treatment goals for osteonecrotic lesions of the jaw include controlling the following aspects: infection, bone necrosis, and pain.⁴ Infection involves cutaneous fistula formation, persistent pus discharge, and intense pain; these characteristics greatly reduce quality of life (QOL) in patients with osteonecrotic lesions of the jaw, such that one of the primary goals of treatment for patients with osteonecrotic lesions of the jaw is maintenance and restoration of QOL. Therefore, a better understanding of QOL is essential for accurately evaluating treatment outcome in patients with osteonecrotic lesions of the jaw. Some studies have been performed regarding assessment of QOL in patients with osteonecrotic lesions of the jaw;⁵⁻⁷ however, to the best of our knowledge, there have been no reports regarding assessment of QOL in both patients with MRONJ and in patients with ORN. We hypothesized that the status of lesions (i.e., the staging of MRONJ and ORN and treatment outcome [healed or unhealed]) may affect patients' QOL. Thus, **OOL** among patients with each stage of unhealed lesions and healed patients was compared. Another specific aim of the current study was to identify symptoms that

negatively affect QOL in patients with unhealed MRONJ or ORN.

Materials and Methods

4 Study design/participants

5 To address the research purpose, the investigators designed and implemented this 6 cross-sectional study protocol which was approved by the Research Ethics Committee of Kobe 7 University Hospital (Approval No. 170022). Patients who had been diagnosed with ORN or 8 MRONJ and had undergone treatment at the Department of Oral and Maxillofacial Surgery, 9 Kobe University Hospital between June 2015 and February 2016 were included. Patients who 10 could not complete the questionnaire because of impaired comprehension (e.g., dementia) 11 were excluded.

The guidelines of the American Association of Oral and Maxillofacial Surgeons were used for diagnosis and staging of MRONJ.⁸ In brief, stage 0 MRONJ comprised radiographic changes alone; stage 1 comprised exposure of bone without symptoms; stage 2 comprised exposure of bone without infection; stage 3 comprised exposure of bone without pathological fracture, extraoral fistula, or osteolysis extending to the inferior aspect of the mandible or sinus floor. Patients with stage 0 MRONJ were excluded from this study. ORN was classified in accordance with the method used by Notani et al.⁹ In brief, stage 1 ORN was confined to the alveolar bone; stage 2 ORN was limited to the alveolar bone and/or mandible above the level of the mandibular alveolar canal; stage 3 ORN involved the mandible below the level of the inferior alveolar canal and was accompanied by skin fistula and/or pathologic fracture. Treatment was classified as conservative therapy (i.e., repeated local irrigation or antibiotic administration when necessary), minimal debridement (i.e., sequestrectomy under local or general anesthesia), and surgical resection (e.g., marginal or segmental

1 mandibulectomy) with or without reconstruction.

2	QOL was assessed in patients with MRONJ and ORN by using the Oral Health Impact
3	Profile (OHIP), a commonly used questionnaire in dental therapeutic decision-making. ¹⁰ The
4	short-form version of the Oral Health Impact Profile (OHIP-14) was developed by Slade, ¹¹ and
5	the reliability and validity of the Japanese version of the OHIP-14 have been confirmed. ¹² In
6	brief, OHIP-14 includes two question items from each of the impact sub-domains (i.e.,
7	functional limitation, physical pain, psychological discomfort, physical disability, psychological
8	disability, social disability, and handicap). Response options are "very often (= 4)," "fairly often
9	(= 3)," "occasionally (= 2)," "hardly ever (= 1)," and "never (= 0)." The highest OHIP-14 score
10	is 56, which indicates that a patient's QOL is greatly impaired. Upon administration of the
11	OHIP-14 questionnaire in 2017, patients were stratified into healed and unhealed groups.
12	Healed osteonecrosis of the jaw was defined as follows: 1) an absence of pain and infection; and
13	2) an absence of exposed or probable exposed bone. ¹³ Unhealed osteonecrosis of the jaw
14	consisted of residual lesions after conservative treatments and recurrent or new lesions after
15	minimal debridement or surgery.
16	The predictor variable was the status of osteonecrosis of the jaws (i.e., the staging
17	of lesions and healing). The outcome variable was OHIP-14. Other confounding variables
18	such as patient age, sex, primary disease, osteonecrosis location (when lesions were found
19	in both maxilla and mandible, the more severe side was selected), and lesion number (i.e.,
20	single or multiple) were retrospectively gathered from electronic medical records.
21	
22	Statistical analysis
23	Statistical analysis was performed using R (R Development Core Team, 2011). Two
24	groups were compared by Student's t test for continuos variables and by Fisher's exact
	6

test for categorical variables. Multiple groups were compared using one-way analysis of variance and Tukey's test. A *P*-value less than 0.05 was considered statistically significant. Results In total, 74 patients (37 men and 37 women) with a mean age of 70.0 (\pm 10.1) years were included. The clinical characteristics of patients with MRONJ and ORN are shown in Table 1. Patients with MRONJ were significantly older than patients with ORN (P=0.008) and the proportion of women was higher among patients with MRONJ (P<0.001). Patients with ORN had multiple lesions significantly more frequently, relative to patients with MRONJ (P=0.009). Conservative and minimal debridement were selected significantly more frequently for patients with MRONJ than for patients with ORN (*P*=0.004), resulting in a significantly higher rate of unhealed lesions (i.e., residual or recurrent) in patients with MRONJ than in patients with ORN (P=0.007). At the time of OHIP-14 questionnaire acquisition, nine of 42 patients with MRONJ (21.4%) and 17 of 32 patients with ORN (53.1%) had been healed by various treatment approaches. The mean total OHIP-14 scores in all groups are shown in **Table 2**. Although OHIP-14 scores increased as MRONJ stage increased, the mean OHIP-14 score was highest in patients with stage 2 ORN. Multiple comparison showed no significant difference of OHIP-14 score among unhealed stage 1, stage 2, stage 3 MRONJ, unhealed stage 1, stage 2, stage 3 ORN, and healed MRONJ and ORN. As shown in Table 3, among patients with unhealed MRONJ, only the "worsened sense of taste" result significantly differed among stages (P=0.027). In patients with unhealed ORN, only the "painful mouth aching" result significantly differed among stages (P=0.041); painful aching was most severe in patients with unhealed stage 2 ORN (Table 4).

1 Discussion

2	Because one of the treatment goals for osteonecrotic lesions of the jaw is maintenance
3	and restoration of QOL, a better understanding of QOL is essential for treatment decision-
4	making and accurately evaluating treatment outcome in patients with MRONJ and ORN. This
5	study aimed to identify symptoms that negatively affected QOL in patients with MRONJ or
6	ORN, and found that worsened sense of taste and pain negatively affected the QOL in patients
7	with unhealed MRONJ and ORN.

The results of the current study demonstrate the reliability and validity of using the OHIP-14 questionnaire to assess QOL in patients with osteonecrosis of the jaw; specifically, greater reduction of QOL was observed in patients with more severe MRONJ (Table 2). The highest mean OHIP-14 score was 18.2 in patients with unhealed stage 3 MRONJ; this finding is similar to that of previous studies. Barrios et al. reported that, at ≥ 6 months post-treatment, the mean OHIP-14 scores of 142 patients who underwent treatment for oral cancer (mean age, 65.2 years) and age-matched controls (mean age, 67.5 years) were 18.9 (\pm 11.8) and 5.9 (\pm 6.2).¹⁴ Schweyen et al. reported that the mean OHIP-14 score of patients who underwent radiation therapy for head and neck cancers (mean age, 57.7 years) before QOL assessment was 19.2 (± 16.1); moreover, patients with oral cavity cancers had a significantly higher mean OHIP-14 score (28.5 ± 14.4) compared with patients who had cancers in other head and neck regions.¹⁵ The only specific questionnaire items for which results significantly differed among stages were "worsened sense of taste" in patients with unhealed MRONJ (Table 3) and "painful mouth aching" in patients with unhealed ORN (Table 4). Notably, the reduction of OOL was greatest in patients with unhealed stage 2 ORN; the pain score was also highest in patients with unhealed stage 2 ORN.

The severity of pain in maxillofacial osteonecrosis is sufficient to cause sleep

1	deprivation and awaken patients. ¹⁶ We previously analyzed pathological changes in the inferior
2	alveolar nerve to understand the underlying mechanism of pain in maxillofacial osteonecrosis. ¹⁵
3	Patients with severe histopathological nerve degeneration (as determined by surgical resection
4	of the mandibular ORN) exhibited slight pain before surgery. In contrast, patients with
5	relatively normal fascicle morphology in the inferior alveolar nerve experienced extreme
6	preoperative pain. ¹⁷ This pain pathology in patients with mandibular ORN appears similar to
7	diabetic neuropathy. Patients exhibit positive symptoms (e.g., pain, paresthesia, and
8	hypoesthesia) in the early and intermediate stages of diabetic neuropathy; in the later stages of
9	disease progression, patients experience negative symptoms (e.g., sensory loss). ¹⁷ Oral surgeons
10	more commonly encounter sensory loss due to pulpitis, which causes severe pain that interferes
11	with sleep; without removal of the infected pulp, necrosis and apical periodontitis occur, which
12	evoke no pain until the onset of acute infection-related inflammation. The current study showed
13	that pain was most severe in patients with unhealed stage 2 ORN, which supports the above-
14	mentioned hypothesis. Pain management may be difficult in patients with osteonecrotic lesions
15	of the jaw. Minimal debridement (intended to preserve the mandibular canal) often fails,
16	especially in patients with ORN. ¹⁸ As shown in Table 1, the proportion of patients who
17	underwent surgical resection was higher in patients with ORN than in patients with MRONJ.
18	This difference is likely because patients with ORN are younger and more often cancer-free
19	than patients with MRONJ. Therefore, patients with ORN are more often eligible for radical
20	surgery, whereas patients with MRONJ are not. However, OHIP-14 scores were high in patients
21	with healed ORN (the majority of whom received surgical resection). Reduction of QOL in
22	healed ORN patients may be due to postoperative sequelae but also late sequelae of
23	irradiation itself. More conservative management approaches (e.g., pentoxifylline, α -
24	tocopherol, and clodronate ¹⁹⁻²¹) are necessary for management of ORN. Importantly, the only

specific questionnaire item for which results significantly differed among stages of unhealed MRONJ was "worsened sense of taste." This result is potentially because patients with MRONJ experience intraoral chronic purulent drainage and anaerobic odor. One of the causes of oral malodor is osteonecrosis.²² Pathological halitosis, an offensive breath odor, negatively influences patients' QOL.²³ This finding indicates that odor management is important for improvement of QOL in patients with osteonecrotic lesions of the jaw.

There were some limitations in the current study. First, it involved a small sample size and heterogeneous population. To assess the efficacy of treatments for osteonecrosis of the jaw, OOL should be evaluated before and after treatment in the same patients, as performed in a previous study.²⁴ Second, the current study did not evaluate various other factors that have been reported to affect QOL in patients with osteonecrosis of the jaw such as dentition status, denture use, hyposalivation, and trismus. Poor dentition affects mastication; this can be evaluated by the questionnaire items: "unsatisfactory diet" and "frequent meal interruptions." These evaluation items can be affected by the statuses of both jaw osteonecrosis and dentition. Finally, the current study included many elderly patients. Although we excluded patients who could not complete the questionnaires because of impaired comprehension (e.g., dementia), some elderly patients required assistance to complete the questionnaires. Potential differences between elderly patients who require assistance and those who do not might have affected the results of the current study.

In conclusion, the current study demonstrated the usefulness of assessing QOL to better understand the statuses of patients with MRONJ and patients with ORN. There was no significant difference of total OHIP-14 score among unhealed stage 1, stage 2, stage 3 MRONJ, unhealed stage 1, stage 2, stage 3 ORN, and healed MRONJ and ORN. The specific questionnaire items for which results significantly differed among patients with

1	unł	nealed MRONJ and patients with unhealed ORN were "worsened sense of taste" and "painful				
2	mouth aching", respectively. Therefore, odor management and pain management are important					
3	goals for treatment of patients with osteonecrosis of the jaw.					
4						
5	Ac	knowledgments				
6	We	thank Ryan Chastain-Gross, Ph.D., from Edanz Group (https://en-author-				
7	ser	vices.edanzgroup.com) for editing a draft of this manuscript.				
8						
9	Re	ferences				
10	1.	Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, et al. Diagnosis and				
11		management of osteonecrosis of the jaw: a systematic review and international consensus. J				
12		Bone Miner Res. 2015; 30: 3-23.				
13	2.	Rice N, Polyzois I, Ekanayake K, Omer O, Stassen LF. The management of				
14		osteoradionecrosis of the jawsa review. Surgeon. 2015; 13: 101-109.				
15	3.	Nabil S, Samman N. Incidence and prevention of osteoradionecrosis after dental extraction				
16		in irradiated patients: a systematic review. Int J Oral Maxillofac Surg. 2011; 40: 229-243.				
17	4.	Nicolatou-Galitis O, Schiødt M, Mendes RA, Ripamonti C, Hope S, et al. Medication-				
18		related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis,				
19		and treatment. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019; 127: 117-135.				
20	5.	Jacobson AS, Zevallos J, Smith M, Lazarus CL, Husaini H, et al. Quality of life after				
21		management of advanced osteoradionecrosis of the mandible. Int J Oral Maxillofac				
22		Surg. 2013; 42: 1121-1128.				
23	6.	Kyrgidis A, Triaridis S, Kontos K, Patrikidou A, Andreadis C, et al. Quality of life in				
24		breast cancer patients with bisphosphonate-related osteonecrosis of the jaws and patients				
		11				

1			
2 3 4	1		with head and neck cancer: a comparative study using the EORTC QLQ-C30 and
5	2		QLQ-HN35 questionnaires. Anticancer Res. 2012; 32: 3527-3534.
7 8 9	3	7.	Miksad RA, Lai KC, Dodson TB, Woo SB, Treister NS, et al. Quality of life implications
10 11	4		of bisphosphonate-associated osteonecrosis of the jaw. Oncologist. 2011; 16: 121-132.
12 13 14	5	8.	Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American
15 16	6		Association of Oral and Maxillofacial Surgeons position paper on medication-related
17 18	7		osteonecrosis of the jaw2014 update. J Oral Maxillofac Surg. 2015; 72: 1938-1956.
19 20 21	8	9.	Notani K, Yamazaki Y, Kitada H, Sakakibara N, Fukuda H, et al. Management of
22 23	9		mandibular osteoradionecrosis corresponding to the severity of osteoradionecrosis and the
24 25 26	10		method of radiotherapy. Head Neck. 2003; 25: 181-186.
20 27 28	11	10.	Schweyen R, Kuhnt T, Wienke A, Eckert A, Hey J. The impact of oral rehabilitation on
29 30	12		oral health-related quality of life in patients receiving radiotherapy for the treatment of
31 32 33	13		head and neck cancer. Clin Oral Investig. 2017; 21: 1123-1130.
34 35	14	11.	Slade GD. Derivation and validation of a short-form oral health impact profile. Community
36 37 38	15		Dent Oral Epidemiol. 1997; 25: 284-290.
39 40	16	12.	Ikebe K, Matsuda K, Morii K, Wada M, Hazeyama T, et al. Impact of dry mouth and
41 42 43	17		hyposalivation on oral health-related quality of life of elderly Japanese. Oral Sug Oral Med
44 45	18		Oral Pathol Oral Radiol Endod. 2007; 103: 216-222.
46 47 48	19	13.	El-Rabbany M, Lam DK, Shah PS, Azarpazhooh A. Surgical management of medication-
49 50	20		related osteonecrosis of the jaw is associated with improved disease resolution: a
51 52	21		retrospective cohort study. J Oral Maxillofac Surg. 2019; 77: 1816-1822
53 54 55			
56 57			
58 59 60			
61 62			12
63 64			
65			

1	14.	Barrios R, Bravo M, Gil-Montoya JA, Martínez-Lara I, García-Medina B, Tsakos G.
2		Oral and general health-related quality of life in patients treated for oral
3		cancer compared to control group. Health Qual Life Outcomes. 2015; 13: 9.
4	15.	Schweyen R, Kuhnt T, Wienke A, Eckert A, Hey J. The impact of oral rehabilitation on
5		oral health-related quality of life in patients receivingradiotherapy for the treatment of head
6		and neck cancer. Clin Oral Investig. 2017; 21: 1123-1130.
7	16.	Bouquot JE, McMahon RE. Neuropathic pain in maxillofacial osteonecrosis. J Oral
8		Maxillofac Surg. 2000; 58: 1003-1020.
9	17.	Hiraoka Y, Akashi M, Wanifuchi S, Kusumoto J, Shigeoka M, et al. Association between
10		pain severity and clinicohistopathologic findings in the mandibular canal and inferior
11		alveolar nerve of patients with advanced mandibular osteoradionecrosis. Oral Surg Oral
12		Med Oral Pathol Oral Radiol. 2018; 126: 264-271.
13	18.	Jacobson AS, Buchbinder D, Hu K, Urken ML. Paradigm shifts in the management of
14		osteoradionecrosis of the mandible. Oral Oncol. 2010; 46: 795-801.
15	19.	Dissard A, P Dang N, Barthelemy I, Delbet C, Puechmaille M, et al. Efficacy of
16		pentoxifylline-tocopherol-clodronate in mandibular osteoradionecrosis. Laryngoscope.
17		2019 Nov 20. doi: 10.1002/lary.28399.
18	20.	Breik O, Tocaciu S, Briggs K, Tasfia Saief S, Richardson S. Is there a role for
19		pentoxifylline and tocopherol in the management of advanced osteoradionecrosis of the
20		jaws with pathological fractures? Case reports and review of the literature. Int J Oral
21		Maxillofac Surg. 2019; 48: 1022-1027.
22	21.	Rivero JA, Shamji O, Kolokythas A. Osteoradionecrosis: a review of pathophysiology,
23		prevention and pharmacologic management using pentoxifylline, α -tocopherol, and
24		clodronate. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017; 124: 464-471.
		13

2	22. Scully C, Greenman J. Halitology (breath odou	:: aetiopathogenesis and management). Oral
	Dis. 2012; 18: 333-345.	

Wu J, Cannon RD, Ji P, Farella M, Mei L. Halitosis: prevalence, risk factors, sources, measurement and treatment - a review of the literature. *Aust Dent J*. 2019 Oct 14. doi: 10.1111/adj.12725.

24. Zanin RF, Ommizolo G, Weber A, Heitz C, de Lima EMS. Oral health-related quality of
life in women with temporomandibular joint disk anterior displacement before and after
disk repositioning and anchoring surgery assessed with the Oral Health Impact Profile

(OHIP-14). Oral Surg Oral Med Oral Pathol Oral Radiol. 2019; 128: 112-116.

	MRONJ (n=42)	ORN (n=32)	<i>P</i> -value
Age	72.9 ± 10.5	66.9 ± 10.5	0.008
Sex			<0.001
Male	8 (19.0)	29 (90.6)	
Female	34 (81.0)	3 (9.4)	
Primary disease			<0.001
Malignant disease	22 (52.4)	32 (100)	
Location			0.243
Mandible	31 (73.8)	28 (87.5)	
Maxilla	11 (26.2)	4 (12.5)	
Lesion			0.009
Single	27 (64.3)	10 (31.2)	
Multiple	15 (35.7)	22 (68.8)	
Treatment			0.004
Conservative	27 (64.3)	21 (65.6)	
Minimal debridement	11 (26.2)	1 (3.2)	
Surgical resection	4 (9.5)	10 (31.2)	
Outcome			0.007
Unhealed	33 (78.6)	15 (46.9)	
Healed	9 (21.4)	17 (53.1)	

1 **Table 1.** Clinical characteristics of patients with MRONJ and ORN who received treatment at

2 our hospital during the study period

3 Bold font indicates differences that are statistically significant.

4 Data are reported as mean \pm standard deviation or number (percentage) of study patients.

5 MRONJ, medication-related osteonecrosis of the jaw; ORN, osteoradionecrosis.

Table 2. Oral Health Impact Profile (OHIP-14) scores of patients in unhealed	and healed osteonecrosis of the jav	VS
---------------------------------------	--	-------------------------------------	----

	MRONJ staging				ORN staging			Healed ORN
	1 (n=16)	2 (n=12)	3 (n=5)	1 (n=2)	2 (n=3)	3 (n=10)	(n=9)	(n=17)
Total OHIP-14	10.12 (7.33)	13.75 (11.61)	18.20 (14.96)	8.50 (9.19)	15.00 (8.19)	13.40 (9.65)	11.00 (8.09)	13.94 (11.36)

Data are reported as mean \pm standard deviation of study patients.

MRONJ, medication-related osteonecrosis of the jaw. ORN, osteoradionecrosis of the jaw.

	M	MRONJ staging*		
	1 (n=16)	2 (n=12)	3 (n=5)	
Age	76.1 ± 10.2	71.7 ± 9.3	61.2 ± 12.6	0.027
Sex				0.1340
Male	5 (31.2)	1 (8.3)	1 (20.0)	
Female	11 (68.8)	11 (91.7)	4 (80.0)	
Primary disease				0.345
Malignant disease	9 (56.2)	5 (41.7)	4 (80.0)	
Location				0.437
Mandible	10 (62.5)	10 (83.3)	4 (80.0)	
Maxilla	6 (37.5)	2 (16.7)	1 (20.0)	
Lesion				0.016
Single	14 (87.5)	8 (66.7)	1 (20.0)	
Multiple	2 (12.5)	4 (33.3)	4 (80.0)	
Treatment				0.114
Conservative	13 (81.2)	8 (66.7)	2 (40.0)	
Minimal debridement	3 (18.8)	4 (33.3)	2 (40.0)	
Surgical resection	0 (0)	0 (0)	1 (20.0)	
OHIP-14				
Functional limitation				
Trouble pronouncing words	1.19 (1.05)	1.00 (1.29)	1.00 (0.71)	0.893
Sense of taste worse	0.50 (0.89)	1.08 (0.95)	2.00 (1.58)	0.027
Physical pain				
Painful aching in your mouth	0.75 (1.00)	1.25 (1.29)	1.40 (0.89)	0.367
Uncomfortable to eat foods	1.19 (1.33)	1.00 (1.35)	1.40 (1.67)	0.855
Psychological discomfort				
Been self-conscious	0.56 (0.81)	1.58 (1.73)	1.60 (1.82)	0.116
Felt tense	0.50 (0.82)	1.25 (1.48)	0.80 (1.10)	0.243
Physical disability				
Diet been unsatisfactory	1.31 (1.20)	1.17 (1.34)	1.80 (1.79)	0.675
Had to interrupt meals	0.75 (0.86)	0.50 (0.80)	1.00 (1.73)	0.621
Psychological disability				
Difficult to relax	0.62 (0.89)	0.92 (0.90)	1.00 (1.00)	0.602
Been embarrassed	0.31 (0.48)	0.83 (0.94)	1.20 (1.30)	0.076
Social disability				
Been irritable with other	0.31 (0.60)	0.67 (0.65)	1.00 (1.73)	0.260

Table 3. Oral Health Impact Profile (OHIP-14) scores of patients with unhealed MRONJ

Difficult doing usual jobs	0.38 (0.81)	0.42 (0.67)	1.40 (1.67)	0.099
Handicap				
Felt life less satisfying	1.00 (0.82)	1.08 (1.24)	1.40 (1.52)	0.778
Totally unable to function	0.75 (0.77)	1.00 (1.13)	1.20 (1.30)	0.632

Data are reported as mean \pm standard deviation or number (percentage) of study patients. *MRONJ*, medication-related osteonecrosis of the jaw.

		ORN staging		
	1 (n=2)	2 (n=3)	3 (n=10)	
Age	60.5 ± 3.5	73.7 ± 9.3	70.5 ± 9.6	0.304
Sex				ns
Male	2 (100)	3 (100)	10 (100)	
Primary disease				ns
Malignant disease	2 (100)	3 (100)	10 (100)	
Location				0.659
Mandible	2 (100)	2 (66.7)	8 (80.0)	
Maxilla	0 (0)	1 (33.3)	2 (20.0)	
Lesion				0.044
Single	1 (50.0)	3 (100)	2 (20.0)	
Multiple	1 (50.0)	0 (0)	8 (80.0)	
Treatment				0.886
Conservative	2 (100)	3 (100)	8 (80.0)	
Minimal debridement	0 (0)	0 (0)	1 (10.0)	
Surgical resection	0 (0)	0 (0)	1 (10.0)	
OHIP-14				
Functional limitation				
Trouble pronouncing words	1.00 (1.41)	1.00 (1.00)	1.70 (1.57)	0.695
Sense of taste worse	0.50 (0.71)	0.67 (1.15)	0.90 (0.74)	0.784
Physical pain				
Painful aching in your mouth	0.50 (0.71)	2.33 (0.58)	0.80 (0.92)	0.041
Uncomfortable to eat foods	0.50 (0.71)	0.67 (1.15)	1.00 (0.82)	0.698
Psychological discomfort				
Been self-conscious	0.50 (0.71)	1.33 (0.58)	1.10 (1.10)	0.660
Felt tense	0.50 (0.71)	1.00 (1.00)	0.50 (0.53)	0.507
Physical disability				
Diet been unsatisfactory	0.50 (0.71)	1.00 (1.00)	1.50 (1.43)	0.614
Had to interrupt meals	0.50 (0.71)	1.00 (1.00)	1.10 (0.88)	0.690
Psychological disability				
Difficult to relax	0.50 (0.71)	0.85 (0.90)	0.80 (0.63)	0.750
Been embarrassed	0.50 (0.71)	0.77 (0.93)	0.80 (0.63)	0.750
Social disability				
Been irritable with other	0.50 (0.71)	1.00 (0)	0.90 (0.74)	0.698
Difficult doing usual jobs	0.50 (0.71)	0.67 (0.58)	0.90 (0.74)	0.725

Table 4. Oral Health Impact Profile (OHIP-14) scores of patients with unhealed ORN

Handicap				
Felt life less satisfying	1.00 (0)	1.00 (0)	0.80 (1.03)	0.921
Totally unable to function	1.00 (0)	1.00 (0)	0.60 (0.70)	0.503

Data are reported as mean ± standard deviation or number (percentage) of study patients.

ORN, osteoradionecrosis of the jaw; ns, not significant.